efficacy of carraguard？-based microbicides in vivo despite variable in vitro activitycarraguard的功效的杀微生物剂体内体外活动尽管变量.pdfVIP

Efficacy of CarraguardH-Based Microbicides In Vivo Despite Variable In Vitro Activity 1¤ 1 1 1 1 1 Stuart G. Turville , Meropi Aravantinou , Todd Miller , Jessica Kenney , Aaron Teitelbaum , Lieyu Hu , 1 1 2 2 2 Anne Chudolij , Tom M. Zydowsky , Michael Piatak Jr. , Julian W. Bess Jr. , Jeffrey D. Lifson , 3 4 1 James Blanchard , Agegnehu Gettie , Melissa Robbiani * 1 Center for Biomedical Research, HIV and AIDS Program, Population Council, New York, New York, United States of America, 2 AIDS and Cancer Virus Program, SAIC- Frederick, Inc., National Cancer Institute, Frederick, Maryland, United States of America, 3 Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana, United States of America, 4 Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America Abstract Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident with demonstrating efficacy in vivo, is central to advancing new generation microbicides. We evaluated CarraguardH and a new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV- 150 (PC-817). Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV reverse transcriptase). Carraguard showed limited activity agains